TGFβRI-IN-2 manufacturers
- TP-008
-
- $1980.00
-
2026-07-27
- CAS:1976038-41-1
- Purity:
- Supply Ability: 10g
- TP-008
-
- $1980.00
-
2026-07-27
- CAS:1976038-41-1
- Purity:
- Supply Ability: 10g
- TP-008
-
- $1980.00
-
2025-08-22
- CAS:1976038-41-1
- Purity:
- Supply Ability: 10g
|
| | TGFβRI-IN-2 Basic information |
| Product Name: | TGFβRI-IN-2 | | Synonyms: | TGFβRI-IN-2;TP-008;TP008,TP 008;3H-Imidazo[4,5-c]pyridine-3-acetamide, 1-[2-(5-chloro-2-fluorophenyl)-5-methyl-4-pyridinyl]-1,2-dihydro-2-oxo- | | CAS: | 1976038-41-1 | | MF: | C20H15ClFN5O2 | | MW: | 411.82 | | EINECS: | | | Product Categories: | | | Mol File: | 1976038-41-1.mol |  |
| | TGFβRI-IN-2 Chemical Properties |
| Boiling point | 664.2±65.0 °C(Predicted) | | density | 1.450±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 2mg/mL, clear | | form | Solid | | pka | 15.82±0.40(Predicted) | | color | White to off-white | | InChI | 1S/C20H15ClFN5O2/c1-11-8-25-15(13-6-12(21)2-3-14(13)22)7-17(11)27-16-4-5-24-9-18(16)26(20(27)29)10-19(23)28/h2-9H,10H2,1H3,(H2,23,28) | | InChIKey | LVEUPFUJRKZPEN-UHFFFAOYSA-N | | SMILES | Fc1c(cc(cc1)Cl)c2ncc(c(c2)[n]3c4c([n]([c]3=O)CC(=O)N)cncc4)C |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | TGFβRI-IN-2 Usage And Synthesis |
| Uses | TP-008 is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose[1]. | | Biological Activity | SGC Frankfurt Pharma donated probe. TP-008 is a cell penetrant, potent and selective ALK4/5 ((activin-like kinase 4/5) dual inhibitor th at potently inhibits SMAD2/3 phosphorylation in C2C12 cells. TP-008 exhibits significant cardiac toxicity in mice. It is compound 18 in BMCL 2016 paper. | | in vivo | TP-008 (oral administation; 50, 150 and 500 mg/kg; 5 days) induces cardiovascular toxicity characterized by valvular interstitial cell proliferation, neutrophil presence, hemorrhage and fibrin deposition in the heart valves[1]. | Animal Model: | Rats[1] | | Dosage: | 50, 150 and 500 mg/kg | | Administration: | Oral administation; 50, 150 and 500 mg/kg; 5 days | | Result: | Induced cardiovalvulopathy in both the medium and high dose animal groups. |
| | References | [1] Wang H, et al. Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.Bioorg Med Chem Lett. 2016 Sep 1;26(17):4334-9. DOI:10.1016/j.bmcl.2016.07.030 |
| | TGFβRI-IN-2 Preparation Products And Raw materials |
|